These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 1680440

  • 1. Aluminum and deferoxamine kinetics in CAPD.
    Mactier RA.
    Adv Perit Dial; 1991; 7():26-9. PubMed ID: 1680440
    [Abstract] [Full Text] [Related]

  • 2. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
    Passlick J, Wilhelm M, Busch T, Grabensee B, Ohnesorge FK.
    Dtsch Med Wochenschr; 1989 Feb 17; 114(7):253-7. PubMed ID: 2917487
    [Abstract] [Full Text] [Related]

  • 3. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U.
    Schweiz Rundsch Med Prax; 1994 Jun 14; 83(24):738-56. PubMed ID: 8023059
    [Abstract] [Full Text] [Related]

  • 4. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia.
    O'Brien AA, McParland C, Keogh JA.
    Nephrol Dial Transplant; 1987 Jun 14; 2(2):117-9. PubMed ID: 3112649
    [Abstract] [Full Text] [Related]

  • 5. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Joffe P, Olsen F, Heaf JG, Gammelgaard B, Pödenphant J.
    Clin Nephrol; 1989 Sep 14; 32(3):133-8. PubMed ID: 2791364
    [Abstract] [Full Text] [Related]

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 14; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 7. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K, Brown ST, Sella M, Trapp G.
    J Lab Clin Med; 1989 Jan 14; 113(1):50-7. PubMed ID: 2909650
    [Abstract] [Full Text] [Related]

  • 8. Recommendations for dietary protein intake in CAPD patients.
    Piraino B.
    Adv Perit Dial; 1996 Jan 14; 12():275-9. PubMed ID: 8865918
    [Abstract] [Full Text] [Related]

  • 9. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD.
    Passlick J, Wilhelm M, Busch T, Grabensee B, Ohnesorge FK.
    Clin Nephrol; 1989 Aug 14; 32(2):96-100. PubMed ID: 2766587
    [Abstract] [Full Text] [Related]

  • 10. The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure.
    Malluche HH, Smith AJ, Abreo K, Faugere MC.
    N Engl J Med; 1984 Jul 19; 311(3):140-4. PubMed ID: 6377067
    [Abstract] [Full Text] [Related]

  • 11. [Desferal treatment of aluminum poisoning; effect on serum concentrations of aluminum (Al), iron (Fe) and copper (Cu)].
    Günther K, Winnefeld K, Stein G, Sperschneider H, Schröter H, Fünfstück R.
    Z Urol Nephrol; 1986 Oct 19; 79(10):569-76. PubMed ID: 3811645
    [Abstract] [Full Text] [Related]

  • 12. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
    Navarro JA, Granadillo VA, Rodríguez-Iturbe B, García R, Salgado O, Romero RA.
    Clin Nephrol; 1991 May 19; 35(5):213-7. PubMed ID: 1855329
    [Abstract] [Full Text] [Related]

  • 13. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA, Ackrill P, Burgess E, Day JP, Domingo JL, Flaten TP, Savory J.
    J Toxicol Environ Health; 1996 Aug 30; 48(6):667-83. PubMed ID: 8772805
    [Abstract] [Full Text] [Related]

  • 14. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE, Johnson CA.
    Clin Pharm; 1985 Aug 30; 4(4):434-9. PubMed ID: 3899471
    [Abstract] [Full Text] [Related]

  • 15. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
    Gallar P, Ortega O, Gutiérrez M, Muñoz M, Hilara L, Oliet A, Rodríguez I, Giménez E, Vigil A.
    Nefrologia; 2000 Aug 30; 20(4):355-61. PubMed ID: 11039261
    [Abstract] [Full Text] [Related]

  • 16. Aluminum removal by peritoneal dialysis: intravenous vs. intraperitoneal deferoxamine.
    Hercz G, Salusky IB, Norris KC, Fine RN, Coburn JW.
    Kidney Int; 1986 Dec 30; 30(6):944-8. PubMed ID: 3820944
    [Abstract] [Full Text] [Related]

  • 17. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P, Day JP.
    Clin Nephrol; 1985 Dec 30; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [Abstract] [Full Text] [Related]

  • 18. Deferoxamine for the treatment of hemosiderosis during CAPD.
    Gomez RA, Campbell F, Savory J, Chevalier RL.
    Int J Pediatr Nephrol; 1987 Dec 30; 8(1):21-4. PubMed ID: 3583552
    [Abstract] [Full Text] [Related]

  • 19. Deferoxamine for aluminum toxicity in dialysis patients.
    Hernandez P, Johnson CA.
    ANNA J; 1990 Jun 30; 17(3):224-8. PubMed ID: 2357118
    [Abstract] [Full Text] [Related]

  • 20. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration.
    Douthat WG, Acuña Aguerre G, Fernández Martín JL, Mouzo R, Cannata Andía JB.
    Nephrol Dial Transplant; 1994 Jun 30; 9(10):1431-4. PubMed ID: 7816256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.